免疫调节治疗——证据何在?
本文综述围种植期免疫调节治疗的临床证据。作者指出,支持免疫抑制治疗用于体外受精患者的临床证据基础薄弱,现有文献存在异质性和发表偏倚等问题,当前证据不支持其临床使用,但更精细的表型分型可能识别获益人群。
要点
- 当前证据基础不支持对体外受精患者临床使用免疫调节治疗。
- 复发性种植失败和妊娠丢失是临床表现而非诊断,需进行表型分型和病因学检查。
- 更精细的表型分型可能识别出可从免疫调节治疗中获益的人群。
核心结论
- 当前证据基础不支持对接受体外受精的患者临床使用免疫调节治疗。
- 更精细的表型分型可能识别出可能获益的人群。
研究设计与样本
- 本文为综述,讨论围种植期免疫调节治疗的临床证据基础。
主要发现
- 支持使用免疫抑制治疗的临床证据基础薄弱,难以在实践中应用,无法满足医生和患者的需求。
- 该领域的文献存在异质性、小样本研究和发表偏倚等挑战,与其他医学领域相同。
- 复发性种植失败和妊娠丢失不是诊断,而是需要适当表型分型和病因学检查的临床表现。
- 我们正日益获得做出「子宫内膜诊断」的工具,这将允许设计针对种植失败 underlying cause 而非症状的干预性临床研究。
临床怎么用
- 当前证据基础不支持对接受体外受精的患者临床使用免疫调节治疗。
- 更精细的表型分型可能识别出可能获益的人群。
局限性
- 该领域文献存在异质性、小样本研究和发表偏倚等挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While advances in assisted reproductive techniques have been substantial, failure of the apparently viable embryo to implant remains a source of distress and frustration to patients and specialists alike. The unique maternal immunological response to the embryo and the notion that defects in early placentation underlie the great complications of pregnancy have focused attention on the therapeutic potential of peri-implantation immunomodulation. On the face of it, the rationale for this approach is very attractive. However, as will be argued in this review, the clinical evidence base supporting the use of immunosuppressive treatments is weak and difficult to apply in practice and fails the needs of both doctors and their patients. This evidence gap is filled by justifications that are based largely on meeting patient expectations and commercial imperatives. However, this does not mean that immunomodulation treatments should be written off as ineffective. The literature in this field, while suffering the same challenges of heterogeneity, small studies, and publication bias as other areas of medicine, does hint at the way forward. Recurrent implantation failure and pregnancy loss are not diagnoses but clinical presentations that require appropriate phenotyping and etiological investigation. We are increasingly gaining the tools to make an "endometrial diagnosis," and these will allow us to design clinical studies of interventions that treat the underlying cause rather than the symptoms of implantation failure. The current evidence base does not support the clinical use of immunomodulation therapies in patients undergoing IVF. However, more discerning phenotyping may identify groups who could benefit.
引用
- Hviid MM, Macklon N. Immune modulation treatments-where is the evidence? Fertil Steril. 2017. PMID: 28501364. doi:10.1016/j.fertnstert.2017.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。